Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 72.14

+3.8%

12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (3172)	11/29/2001 10:35:35 AM
From: tuck	Read Replies (1) of 4676

SB, Well, they're not saying a lot. They're using complete clinical remission as the primary endpoint, same as before. So far as I know, only the dose has changed, but I don't know what it is. The only reference to dosing I've seen is here: Message 14509638 2mg/kg wasn't enough to give every patient sufficient exposure to the drug. I'd have to dig way back to find MTD, etc. I wouldn't expect the new dose to be higher than 3mg/kg, but I know nada. This stuff is supposed to be dealt with in PII. Wonder how the designs/analyses were sufficiently flawed to reduce the PIII to a "pilot study" (which I'll call a PIIc). Hope the the clinical developers responsible are elsewhere now. Haven't paid attention to see if other players in the Crohn's market have put this 18 month stumble to good use. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next